Literature DB >> 34089725

The S100 protein family in lung cancer.

Ting Wang1, Ge Du2, Dong Wang3.   

Abstract

The S100 protein family is involved in the pathogenesis of several malignancies including lung cancer. Recent studies have shown that one member, S100A2, was over-expressed in advanced stage non-small cell lung cancer (NSCLC). Another, S100A6, demonstrated variable expression in different lung cancer subtypes. Research using NSCLC cell lines reported that SIX3 inhibited cell metastasis and proliferation via S100P down-regulation. This review represents an update on S100 proteins in lung cancer from 2017 to 2021 and includes the aforementioned as well as S100A4, S100A7, and S100B. Inconsistencies in mechanisms of action for S100A8/S100A9 are highlighted and a comprehensive evaluation of the most recent evidence for the S100 proteins in lung cancer is presented.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lung cancer; S100 protein family; S100A2; S100A6; S100B

Year:  2021        PMID: 34089725     DOI: 10.1016/j.cca.2021.05.028

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

Review 1.  SIX3 function in cancer: progression and comprehensive analysis.

Authors:  Tian-Liang Ma; Peng Zhu; Jing-Xian Chen; Yi-He Hu; Jie Xie
Journal:  Cancer Gene Ther       Date:  2022-06-28       Impact factor: 5.987

2.  Expression of S100A9 and KL-6 in common interstitial lung diseases.

Authors:  Li Lin; Yabin Zhao; Zhenhua Li; Yun Li; Wei Wang; Jian Kang; Qiuyue Wang
Journal:  Medicine (Baltimore)       Date:  2022-04-29       Impact factor: 1.817

Review 3.  S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Etienne Delangre; Ezia Oppliger; Serkan Berkcan; Monika Gjorgjieva; Marta Correia de Sousa; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

4.  Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma.

Authors:  Qiaxuan Li; Daipeng Xie; Lintong Yao; Hongrui Qiu; Peimeng You; Jialong Deng; Congsen Li; Weijie Zhan; Maotao Weng; Shaowei Wu; Fasheng Li; Yubo Zhou; Fanjun Zeng; Yong Zheng; Haiyu Zhou
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.